TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37865755

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) of the occipital nerves for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Burst occipital nerve stimulation (ONS) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tonic occipital nerve stimulation (ONS) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TENS as a preoperative screening tool
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (deactivated ONS system) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Burst ONS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tonic ONS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduction in headache pain intensity (numeric rating scale)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduction in background headache
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient's impression of change (PGIC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (EuroQoL-5D)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety and depression (Hospital Anxiety and Depression Scale, HADS)
Number of subjects: 40
Study: 37865771

Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa (1 mg/kg every 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Agalsidase alfa (0.2 mg/kg every 2 weeks)
Number of subjects: 20
Study: 37865776

Group type: EXPERIMENTAL
Intervention: Pre-ICI collections from patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pre-ICI collections from patients with irAEs G ≥ 2
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Post-treatment collections from subjects experiencing irAEs G ≥ 2
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Post-treatment collections after steroids
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 114
Study: 37865777

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing at Intake (MII)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard comprehensive intake assessment (intake-as-usual [IAU])
Number of subjects: 150
Study: 37865807

Group type: EXPERIMENTAL
Intervention: COMORAL (multi-channeled oral irrigation unit) used 3 times a day, 5 days a week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no supplementary oral hygiene products, brushing 1-2 times a day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: COMORAL (multi-channeled oral irrigation unit)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 37865896

Group type: EXPERIMENTAL
Intervention: Lazertinib (240 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gefitinib (250 mg/d)
Number of subjects: 86
Study: 37866094

Group type: EXPERIMENTAL
Intervention: Molecular point-of-care tests for infectious disease diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular point-of-care tests
Number of subjects: 0
Study: 37866369

Group type: EXPERIMENTAL
Intervention: Children and Young People's Health Partnership (CYPHP) model of care
Number of subjects: 97970

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 97970
Study: 37866373

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2399
Study: 37866442

Group type: EXPERIMENTAL
Intervention: Substance use services that were women-led, safe, and responsive to women's needs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Experiences of gender-based violence in substance use service settings
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cycle of trauma and drug use exacerbated by oppression in substance use services settings
Number of subjects: 36
Study: 37866460

Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg twice daily for 52 weeks
Number of subjects: 230
Study: 37866669

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT) with cyclophosphamide 200 mg/Kg and rituximab 1000 mg
Number of subjects: 21
Study: 37867141

Group type: COMPARATOR
Intervention: CASR rs1042636
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IRF2BP1 rs60158447 GC genotype
Number of subjects: 75
Study: 37867184

Group type: EXPERIMENTAL
Intervention: Headaches reported at M12
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Pre-existing headaches before meningitis
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Higher neutrophilic polynuclei percentage in CSF
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Brain abscess during initial hospitalization
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: M12 neuro-functional disability
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: M12 physical handicap
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: M12 depressive symptoms
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: M12 altered physical quality of life
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: M12 altered mental quality of life
Number of subjects: 277
Study: 37867420

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 37867765

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Business-as-usual (control)
Number of subjects: 0
Study: 37868294

Group type: EXPERIMENTAL
Intervention: Brushing with a denture brush and chlorhexidine (CHX) toothpaste
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lacalut cleaning tablet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of brushing and Lacalut cleaning tablet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Polished acrylic fitting surface
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Unpolished acrylic fitting surface
Number of subjects: 39
Study: 37868598

Group type: EXPERIMENTAL
Intervention: Mindfulness training and yoga
Number of subjects: 40

Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 40
Study: 37868626

Group type: EXPERIMENTAL
Intervention: Cardiac-derived c-kit+ progenitor cells (CPCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPC-derived extracellular vesicles (CPC-EV)
Number of subjects: 0
Study: 37868649

Group type: EXPERIMENTAL
Intervention: Acthar Gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 37868660

Group type: EXPERIMENTAL
Intervention: Supervised multicomponent exercise program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation at home (control group)
Number of subjects: 66
Study: 37868796

Group type: EXPERIMENTAL
Intervention: Faricimab treatment
Number of subjects: 185
Study: 37868959

Group type: EXPERIMENTAL
Intervention: CORFU questionnaire
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (endothelin-1, von Willebrand factor, Interleukin-1 Receptor antagonist)
Number of subjects: 148
Study: 37869030

Group type: EXPERIMENTAL
Intervention: Intravitreal lampalizumab 10 mg every 4 weeks (LQ4W)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Intravitreal lampalizumab 10 mg every 6 weeks (LQ6W)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Sham procedures (pooled)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: All groups (LQ4W, LQ6W, pooled sham)
Number of subjects: 197
Study: 37869085

Group type: EXPERIMENTAL
Intervention: Regorafenib (80 mg once daily on days 1-21 of each 28 days cycle) + Toripalimab (240 mg, q3w) + High-dose radiotherapy (4-8 fractions of 8-12Gy) and Low-dose radiotherapy (1-10Gy at 0.5-2Gy/fraction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regorafenib (120 mg once daily on days 1-21 of each 28 days cycle)
Number of subjects: 0
Study: 37869139

Group type: EXPERIMENTAL
Intervention: Vertigoheel treatment for 2 months
Number of subjects: 54
Study: 37869160

Group type: EXPERIMENTAL
Intervention: AI as a Medical Device (AIaMD) using images taken by iPhone 6S
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: AI as a Medical Device (AIaMD) using images taken by Samsung 10
Number of subjects: 572
Study: 37869360

Group type: EXPERIMENTAL
Intervention: Rilzabrutinib 400 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37869406

Group type: EXPERIMENTAL
Intervention: Neuropilin-1 (NRP-1)
Number of subjects: 0
Study: 37869523

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 307
Study: 37869881

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 37869974

Group type: EXPERIMENTAL
Intervention: Voice interactive sleep log
Number of subjects: 17

Group type: COMPARATOR
Intervention: Paper and pencil logs
Number of subjects: 17

Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 17
Study: 37870112

Group type: COMPARATOR
Intervention: recombinant activated factor VII (rFVIIa)
Number of subjects: 4652

Group type: COMPARATOR
Intervention: antifibrinolytic drugs
Number of subjects: 4652

Group type: COMPARATOR
Intervention: platelet transfusion
Number of subjects: 4652

Group type: EXPERIMENTAL
Intervention: prothrombin complex concentrates (PCC)
Number of subjects: 4652
Study: 37870130

Group type: COMPARATOR
Intervention: Oral antibiotics (various types including penicillins, cephalosporins, macrolides, and trimethoprim) for 10-14 days
Number of subjects: 2581

Group type: COMPARATOR
Intervention: Oral antibiotics
Number of subjects: 2581
Study: 37870148

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 2266
Study: 37870163

Group type: EXPERIMENTAL
Intervention: SB16 (60 mg dose)
Number of subjects: 168

Group type: COMPARATOR
Intervention: EU-DEN (60 mg dose)
Number of subjects: 168

Group type: COMPARATOR
Intervention: US-DEN (60 mg dose)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: SB16, EU-DEN, US-DEN
Number of subjects: 168
Study: 37870228

Group type: EXPERIMENTAL
Intervention: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy delivering 12.5 Gy to the tumor bed.
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy.
Number of subjects: 358
Study: 37870369

Group type: EXPERIMENTAL
Intervention: Crossover feet
Number of subjects: 2

Group type: COMPARATOR
Intervention: Energy-storing feet
Number of subjects: 2
Study: 37870510

Group type: EXPERIMENTAL
Intervention: Nonhormonal selective NK3R antagonist
Number of subjects: 0
Study: 37870536

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Number of subjects: 267
Study: 37870597

Group type: EXPERIMENTAL
Intervention: Intervention website
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control website
Number of subjects: 89
Study: 37870808

Group type: EXPERIMENTAL
Intervention: Health-related conversations about healthy eating and physical activity
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Weight-related conversations
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Mealtime media use (television/movie watching)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Health-related conversations
Number of subjects: 344
Study: 37870836

Group type: EXPERIMENTAL
Intervention: ACTH-stimulated AVS
Number of subjects: 228

Group type: COMPARATOR
Intervention: Non-ACTH-stimulated AVS
Number of subjects: 228
Study: 37870862

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg per day maximum-tolerated dose)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Topiramate (per-protocol analysis)
Number of subjects: 132
Study: 37870871

Group type: EXPERIMENTAL
Intervention: mt-sRNA test
Number of subjects: 8920
Study: 37870920

Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 266

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 266
Study: 37870947

Group type: EXPERIMENTAL
Intervention: Anal Human Papillomavirus Home Self-Sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician Sampling
Number of subjects: 0
Study: 37870949

Group type: EXPERIMENTAL
Intervention: Nivolumab plus gemcitabine-cisplatin
Number of subjects: 608

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin alone
Number of subjects: 608
Study: 37870954

Group type: EXPERIMENTAL
Intervention: Oral tamoxifen citrate, 20 mg/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4-hydroxytamoxifen gel, 2 mg/d per breast
Number of subjects: 100
Study: 37870955

Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (investigator's choice of therapy with pembrolizumab, ipilimumab, or dacarbazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 37870968

Group type: EXPERIMENTAL
Intervention: 960-mg sotorasib-panitumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 240-mg sotorasib-panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 0
Study: 37870969

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 291

Group type: COMPARATOR
Intervention: Cabozantinib or Vandetanib (Control)
Number of subjects: 291
Study: 37870974

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study: 37870973

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control treatment (platinum-based chemotherapy with or without pembrolizumab)
Number of subjects: 212
Study: 37870976

Group type: EXPERIMENTAL
Intervention: Amivantamab-chemotherapy
Number of subjects: 308

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 308
Study: 37871102

Group type: EXPERIMENTAL
Intervention: ETCO2 detection using sidestream capnography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 0
Study: 37871300

Group type: EXPERIMENTAL
Intervention: U2-VeN (venetoclax, umbralisib, and ublituximab)
Number of subjects: 51
Study: 37871306

Group type: EXPERIMENTAL
Intervention: Blinatumomab consolidation after auto-SCT
Number of subjects: 14
Study: 37871309

Group type: EXPERIMENTAL
Intervention: Enasidenib (ENA) monotherapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Enasidenib (ENA) with azacitidine
Number of subjects: 77
Study: 37871332

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 104
Study: 37871403

Group type: EXPERIMENTAL
Intervention: CNSI patients overall
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Encephalitis
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Meningitis
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Brain abscess
Number of subjects: 451
Study: 37871452

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: STAIR
Number of subjects: 92

Group type: COMPARATOR
Intervention: SNT
Number of subjects: 92
Study: 37871528

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 316
Study: 37871555

Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) with dolutegravir or darunavir/cobicistat plus lamivudine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple therapy (TT) with integrase inhibitors
Number of subjects: 40
Study: 37871576

Group type: EXPERIMENTAL
Intervention: Giroctocogene fitelparvovec gene therapy (3 × 10^13 vg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Giroctocogene fitelparvovec gene therapy
Number of subjects: 11
Study: 37871603

Group type: EXPERIMENTAL
Intervention: Neonatal listeriosis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Gestational age-matched control children without infection
Number of subjects: 53
Study: 37871604

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Number of subjects: 698

Group type: COMPARATOR
Intervention: Placebo combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Number of subjects: 698
Study: 37871608

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab (1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 668
Study: 37871684

Group type: EXPERIMENTAL
Intervention: Pain Disability Index (PDI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Short Form 36-item mental component (SF-36 MC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Short Form 36-item physical component (SF-36 PC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined effect of all pain cognitions on SF-36 PC
Number of subjects: 120
Study: 37871703

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV) administered on days 1 + 8 of a 21-day cycle until progression or unacceptable toxicity.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 8 mg/kg with Enfortumab vedotin (EV) 1.25 mg/kg with granulocyte colony-stimulating factor support; MTDs are SG 10 mg/kg with EV 1.25 mg/kg.
Number of subjects: 23
Study: 37871747

Group type: EXPERIMENTAL
Intervention: Homestead food production intervention
Number of subjects: 2701
Study: 37871751

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 37871841

Group type: EXPERIMENTAL
Intervention: Snare Tip Soft Coagulation (STSC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation (APC)
Number of subjects: 384

Group type: COMPARATOR
Intervention: No Margin Treatment (Control)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 384
Study: 37871959

Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: sTNFR1
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: EGF and arginine-to-citrulline ratio
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Baseline sTNFR1, uromodulin, and EGF concentrations
Number of subjects: 244
Study: 37871997

Group type: EXPERIMENTAL
Intervention: Early intensive and sustained vasodilatation
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study: 37872020

Group type: EXPERIMENTAL
Intervention: Toripalimab plus axitinib (240 mg intravenously once every 3 weeks + 5 mg orally twice daily)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily for 4 weeks or 2 weeks)
Number of subjects: 421
Study: 37872059

Group type: EXPERIMENTAL
Intervention: 0.05% CsA-CE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% CsA-CE
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% CsA-CE and 0.1% CsA-CE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 37872092

Group type: EXPERIMENTAL
Intervention: Different diagnostic criteria for assessing mild micro-hepatic encephalopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37872225

Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CLDN6
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CLDN6 plus CARVac
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher dose level (DL) treatment
Number of subjects: 22
Study: 37872479

Group type: EXPERIMENTAL
Intervention: Transitional Care Stroke Intervention (TCSI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study: 37872492

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37872497

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 120
Study: 37872499

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enema +
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enema ÷
Number of subjects: 8
Study: 37872504

Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) Trial
Number of subjects: 76
Study: 37872582

Group type: EXPERIMENTAL
Intervention: MI plus omega 3
Number of subjects: 483

Group type: COMPARATOR
Intervention: Combined intervention (MI plus omega 3)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 37872617

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SEP)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Home-based structured exercise program (HSEP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Walk advice (WA)
Number of subjects: 166
Study: 37872628

Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation (LLTS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham LLTS
Number of subjects: 100
Study: 37872639

Group type: EXPERIMENTAL
Intervention: Counseling on safe use of prescribed opioids
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Opioids prescribed at discharge
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Adolescent survey on discussions about safe use of pain medications
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: AOD screening results
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Counseling documentation by sex, age, race, ethnicity, and AOD use
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Adolescent survey results on counseling
Number of subjects: 247
Study: 37872654

Group type: EXPERIMENTAL
Intervention: Hierarchical Composite End Point (HCE)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Win Odds (WO) for treatment effects on HCE
Number of subjects: 7

Group type: COMPARATOR
Intervention: Hazard Ratio (HR) of the primary kidney outcome
Number of subjects: 7